28‐Day all cause mortality (adult studies) · adult patients with sepsis, severe sepsis and septic shock
Polyclonal intravenous immunoglobulin (IVIG) probably leads to lower all‐cause mortality, adults, standard polyclonal IVIG compared with placebo or no intervention (moderate certainty).
5 findings from 1 review
RR 0.81 [0.7, 0.93]
10 studies · 1430 participants
Moderate
RR 0.66 [0.51, 0.85]
7 studies · 528 participants
Moderate
RR 0.97 [0.81, 1.15]
5 studies · 945 participants
High
Show 2 more findings
All‐cause mortality, neonates, standard polyclonal IVIG · neonates with sepsis, severe sepsis and septic shock
Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in all‐cause mortality, neonates, standard polyclonal IVIG compared with placebo or no intervention (moderate certainty).
2 findings from 1 review
All‐cause mortality, neonates, IgM‐enriched polyclonal IVIG · neonates with sepsis, severe sepsis and septic shock
Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in all‐cause mortality, neonates, IgM‐enriched polyclonal IVIG compared with placebo or no intervention (low certainty).
1 finding from 1 review
All‐cause mortality · patients with intravenous administration set replacement
Primary analysis: less may leads to higher mortality compared with more frequent (low certainty).
1 finding from 1 review
Anti‐cytokine, all‐cause mortality ‐ uncertain risk of bias · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies probably leads to lower anti‐cytokines versus placebo, all‐cause mortality compared with placebo (moderate certainty).
3 findings from 1 review
RR 0.92 [0.86, 0.97]
9 studies · 7893 participants
Moderate
RR 0.91 [0.86, 0.97]
7 studies · 7752 participants
Moderate
RR 0.89 [0.8, 1]
4 studies · 2687 participants
Moderate
Anti‐endotoxin ‐ HA‐1A versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
It is very uncertain whether monoclonal antibodies changes anti‐endotoxin ‐ HA‐1A versus placebo, all‐cause mortality compared with placebo (very low certainty).
3 findings from 1 review
RR 0.8 [0.54, 1.2]
3 studies · 2668 participants
Very low
RR 1.01 [0.94, 1.09]
6 studies · 4443 participants
Moderate
RR 0.92 [0.79, 1.06]
8 studies · 4676 participants
Low
Anti‐endotoxin E5 versus placebo, all‐ cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxin E5 versus placebo, all‐ cause mortality compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs incretin‐based control [d. 52 weeks to... · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxin, all‐cause mortality ‐ unclear risk of bias compared with placebo (moderate certainty).
1 finding from 1 review
Anti‐endotoxins Anti‐LPS versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxins Anti‐LPS versus placebo, all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
Anti‐cytokine, all‐cause mortality ‐ low risk of bias studies · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies leads to lower anti‐cytokine, all‐cause mortality ‐ low risk of bias studies compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality ‐ sensitivity analysis · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxin, all‐cause mortality ‐ low risk of bias studies compared with placebo (moderate certainty).
1 finding from 1 review
Anticytokine ‐ anti‐TNF‐alpha versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies probably leads to lower anticytokine ‐ anti‐TNF‐alpha versus placebo, all‐cause mortality compared with placebo (moderate certainty).
1 finding from 1 review
Anti‐cytokines ‐ human interleukin‐1receptor antagonist versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐cytokines ‐ human interleukin‐1receptor antagonist versus… compared with placebo (moderate certainty).
1 finding from 1 review